Clinical Features and Management of Women with Borderline Ovarian Tumors in a Single Center in Brazil

Abstract

Objective The aim of the present study was to describe and analyze data of 57 women with borderline ovarian tumors (BOTs) regarding histological characteristics, clinical features and treatment management at the Department of Obstetrics and Gynecology of the Universidade Estadual de Campinas (Unicamp, in the Portuguese acronym).

Methods The present retrospective study analyzed data obtained from clinical and histopathological reports of women with BOTs treated in a single cancer center between 2010 and 2018.

Results A total of 57 women were included, with a mean age of 48.42 years old (15.43–80.77), of which 30 (52.63%) were postmenopausal, and 18 (31.58%) were < 40 years old. All of the women underwent surgery. A total of 37 women (64.91%) were submitted to complete surgical staging for BOT, and none (0/57) were submitted to pelvic or paraortic lymphadenectomy. Chemotherapy was administered for two patients who recurred. The final histological diagnoses were: serous in 20 (35.09%) cases, mucinous in 26 (45.61%), seromucinous in 10 (17.54%), and endometrioid in 1 (1.75%) case. Intraoperative analyses of frozen sections were obtained in 42 (73.68%) women, of which 28 (66.67%) matched with the final diagnosis. The mean follow-up was of 42.79 months (range: 2.03–104.87 months). Regarding the current status of the women, 45 (78.95%) are alive without disease, 2 (3.51%) are alive with disease, 9 (15.79%) had their last follow-up visit > 1 year before the performance of the present study but are alive, and 1 patient (1.75%) died of another cause.

Conclusion Women in the present study were treated according to the current guidelines and only two patients recurred.

Resumo

Objetivo O objetivo do presente estudo foi descrever uma série de 57 mulheres com tumores borderline de ovário (TBO) em relação às características histológicas, clínicas, e ao manejo do tratamento realizado no Departamento de Obstetrícia e Ginecologia da Universidade Estadual de Campinas (Unicamp).

Métodos O presente estudo retrospectivo analisou dados obtidos dos registros clínicos e histopatológicos de mulheres com TBO tratadas em um único centro oncológico de 2010 a 2018.

Resultados Um total de 57 mulheres foram incluídas, com uma média de idade de 48,42 anos (15,43–80,77), das quais 30 (52,63%) eram menopausadas, e 18 (31,58%) tinham < 40 anos. Todas as mulheres foram operadas. Um total de 37 mulheres (64,91%) foram submetidas a cirurgia de estadiamento completo para TBO, e nenhuma foi submetida a linfadenectomia pélvica ou paraórtica. O tratamento com quimioterapia foi administrado em duas pacientes que recidivaram. Os diagnósticos histológicos finais foram: seroso em 20 mulheres (35,09%), mucinoso em 26 (45,61%), seromucinoso em 10 (17,54%) e endometrióide em 1 (1,75%). A avaliação histológica intraoperatória foi realizada em 42 (73,68%) das mulheres, das quais 28 (66,67%) foram compatíveis com os diagnósticos finais. O tempo médio de seguimento foi de 42,79 meses (variando de 2,03 a 104,87 meses). Em relação ao status atual das mulheres, 45 (78.95%) estão vivas sem doença, 2 (3,51%) estão vivas com doença, 9 (15.79%) tiveram a última consulta de seguimento há > 1 ano antes da realização do presente estudo, mas estão vivas, e 1 paciente faleceu por outra causa.

Conclusão As mulheres do presente estudo foram tratadas de acordo com as recomendações atuais e apenas duas mulheres apresentaram recorrência.

Keywords

borderline ovarian tumor (BOT) - treatment - fertility sparing surgery - recurrence

Palavras-chave

tumores borderline de ovário (TBO) - tratamento - cirurgia preservadora de fertilidade - recorrência

Contributors

All of the authors contributed with the project and the interpretation of data, with the writing of the article, with the critical review of the intellectual content, and with the final approval of the version to be published.

• References

• 1 Fischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, treatment, and follow-up of borderline ovarian tumors. Oncologist 2012; 17 (12) 1515-1533 . Doi: 10.1634/theoncologist.2012-0139
• 2 Gershenson DM. Management of borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol 2017; 41: 49-59 . Doi: 10.1016/j.bpobgyn.2016.09.012
• 3 Araujo KG, Jales RM, Pereira PN. , et al. Performance of the IOTA ADNEX model in preoperative discrimination of adnexal masses in a gynecological oncology center. Ultrasound Obstet Gynecol 2017; 49 (06) 778-783 . Doi: 10.1002/uog.15963
• 4 Gizzo S, Berretta R, Di Gangi S. , et al. Borderline ovarian tumors and diagnostic dilemma of intraoperative diagnosis: could preoperative He4 assay and ROMA score assessment increase the frozen section accuracy? A multicenter case-control study. BioMed Res Int 2014; 2014: 803598 . Doi: 10.1155/2014/803598
• 5 Huang Z, Li L, Li C. , et al. Diagnostic accuracy of frozen section analysis of borderline ovarian tumors: a meta-analysis with emphasis on misdiagnosis factors. J Cancer 2018; 9 (16) 2817-2824 . Doi: 10.7150/jca.25883
• 6 Shah JS, Mackelvie M, Gershenson DM. , et al. Accuracy of intraoperative frozen section diagnosis of borderline ovarian tumors by hospital type. J Minim Invasive Gynecol 2019; 26 (01) 87-93 . Doi: 10.1016/j.jmig.2018.04.005
• 7 Lou T, Yuan F, Feng Y, Wang S, Bai H, Zhang Z. The safety of fertility and ipsilateral ovary procedures for borderline ovarian tumors. Oncotarget 2017; 8 (70) 115718-115729 . Doi: 10.18632/oncotarget.23021
• 8 National Cancer Institute. Ovarian Low Malignant Potential Tumors Treatment (PDQ®)-Health Professional Version: Early-Stage Ovarian Low Malignant Potential Tumors. 2015. https://www.cancer.gov/types/ovarian/hp/ovarian-low-malignant-treatment-pdq#section/_11 . Accessed November 15, 2018
• 9 Helpman L, Yaniv A, Beiner ME. , et al. Fertility preservation in women with borderline ovarian tumors - how does it impact disease outcome? A cohort study. Acta Obstet Gynecol Scand 2017; 96 (11) 1300-1306 . Doi: 10.1111/aogs.13203
• 10 Malpica A, Longacre TA. Prognostic indicators in ovarian serous borderline tumours. Pathology 2018; 50 (02) 205-213 . Doi: 10.1016/j.pathol.2017.12.001
• 11 Kurman RJ, Carcangiu ML, Herrington CS, Young RH. World Health Organization Classification of Tumours of Female Reproductive Organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014
• 12 Prat J. ; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014; 124 (01) 1-5 . Doi: 10.1016/j.ijgo.2013.10.001
• 13 Ministério da Economia. Receita Federal. Comprovante de Situação Cadastral no CPF. https://www.receita.fazenda.gov.br/Aplicacoes/SSL/ATCTA/CPF/ConsultaSituacao/ConsultaPublica.asp . Accessed November 15, 2018
• 14 R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2016 https://www.R-project.org/ . Accessed November 15, 2018
• 15 Koensgen D, Weiss M, Assmann K. , et al. Characterization and management of borderline ovarian tumors - results of a retrospective, single-center study of patients treated at the department of gynecology and obstetrics of the University Medicine Greifswald. Anticancer Res 2018; 38 (03) 1539-1545 . Doi: 10.21873/anticanres.12382
• 16 May J, Skorupskaite K, Congiu M. , et al. Borderline ovarian tumors: fifteen years' experience at a Scottish Tertiary Cancer Center. Int J Gynecol Cancer 2018; 28 (09) 1683-1691 . Doi: 10.1097/IGC.0000000000001364
• 17 Vasconcelos I, Darb-Esfahani S, Sehouli J. Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates. BJOG 2016; 123 (04) 498-508 . Doi: 10.1111/1471-0528.13840
• 18 Matsuo K, Machida H, Takiuchi T. , et al. Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. Gynecol Oncol 2017; 144 (03) 496-502 . Doi: 10.1016/j.ygyno.2017.01.019
• 19 De Decker K, Speth S, Ter Brugge HG. , et al. Staging procedures in patients with mucinous borderline tumors of the ovary do not reveal peritoneal or omental disease. Gynecol Oncol 2017; 144 (02) 285-289 . Doi: 10.1016/j.ygyno.2016.11.035
• 20 Cosyns S, De Sutter P, Tournaye H, Polyzos NP. Necessity of appendectomy for mucinous borderline ovarian tumors. Systematic review. Arch Gynecol Obstet 2016; 294 (06) 1283-1289
• 21 Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch 2017; 470 (02) 125-142 . Doi: 10.1007/s00428-016-2040-8
• 22 Uzan C, Nikpayam M, Ribassin-Majed L. , et al. Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments. Ann Oncol 2014; 25 (07) 1312-1319 . Doi: 10.1093/annonc/mdu139